Milestone Pharmaceuticals

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Milestone Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 3 completed later-stage tilt upper quartile by trial count

Milestone Pharmaceuticals: 7 sponsored US clinical trials, 1 recruiting.

Milestone Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Paroxysmal Supraventricular Tachycardia, with 2 trials.

Upper-quartile sponsor footprint

Milestone Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 2

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

NCT05763953
COMPLETED Phase 3

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

NCT04952610
COMPLETED Phase 3

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

NCT04072835
TERMINATED Phase 3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996
TERMINATED Phase 3

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
TERMINATED

The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.

NCT03353610
COMPLETED Phase 2

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 4

Therapeutic Areas

Paroxysmal Supraventricular Tachycardia 2

Where Milestone Pharmaceuticals enrollment is open (later-stage tilt)

1 recruiting of 7 indexed (14% open); 3 completed (43%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Paroxysmal Supraventricular Tachycardia (2 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Milestone Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Milestone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share Milestone Pharmaceuticals3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Milestone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Milestone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Milestone Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of Milestone Pharmaceuticals or any single study.

  • 1 of Milestone Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Paroxysmal Supraventricular Tachycardia is the condition Milestone Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Paroxysmal Supraventricular Tachycardia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Milestone Pharmaceuticals pipeline card: 7 registered trials from official public datasets.Report a data error.